Lexicon Pharmaceuticals, Inc. Stock price Nasdaq
Equities
US5288721047
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 18.65M | Sales 2025 * | 77.52M | Capitalization | 539M |
---|---|---|---|---|---|
Net income 2024 * | -186M | Net income 2025 * | -163M | EV / Sales 2024 * | 28.9 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 6.96 x |
P/E ratio 2024 * |
-3.08
x | P/E ratio 2025 * |
-3.45
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.01% |
Latest transcript on Lexicon Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 14-07-06 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 98-12-31 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-08-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 79 | 01-01-31 |
Ray Debbane
CHM | Chairman | 69 | 07-07-31 |
Director/Board Member | 65 | 07-08-27 |
1st Jan change | Capi. | |
---|---|---|
+2.57% | 108B | |
+9.67% | 104B | |
+6.58% | 23.66B | |
-12.38% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.22% | 16.19B | |
+4.14% | 13.72B | |
+34.31% | 12.22B |